Current Oncology Reports

, Volume 9, Issue 2, pp 120–123 | Cite as

Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors



Lenalidomide is a novel analog of thalidomide with both immunomodulatory and antiangiogenic properties that are more potent than those same properties in the parent compound. Work in several antiangiogenic model systems has provided early evidence of potential mechanisms of its clinical activity. Recent US Food and Drug Administration approval of lenalidomide for patients with deletion 5q myelodysplastic syndromes and advanced multiple myeloma has provided impetus for further evaluation of this agent in solid tumors.


Vascular Endothelial Growth Factor Multiple Myeloma Docetaxel Thalidomide Lenalidomide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Knight R: IMiDs: a novel class of immunomodulators. Semin Oncol 2005, 32(4 Suppl 5):S24–S30.PubMedCrossRefGoogle Scholar
  2. 2.
    List A, Kurtin S, Roe D, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549–557.PubMedCrossRefGoogle Scholar
  3. 3.
    Weber D, Chen C, Niesvizky R, et al.: Lenalidomide plus high-cose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American Phase III Study (MM-009) [abstract]. Proc ASCO 2006, 24:427 (abstract 7521).Google Scholar
  4. 4.
    D’Amato R, Loughnan M, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:368–378.Google Scholar
  5. 5.
    Bauer K, Dixon S, Figg W: Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem Pharmacol 1998, 55:1827–1834.PubMedCrossRefGoogle Scholar
  6. 6.
    Dredge K, Marriott J, Macdonald C, et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87:1166–1172.PubMedCrossRefGoogle Scholar
  7. 7.
    Dredge K, Horsfall R, Robinson S, et al.: Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and akt phosphorylation in vitro. Microvas Res 2005, 69:56–63.CrossRefGoogle Scholar
  8. 8.
    Norby K: Vascular endothelial growth factor and de novo mammalian angiogensis. Microvasc Res 1996, 51:154–163.CrossRefGoogle Scholar
  9. 9.
    Gupta D, Treon S, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950–1961.PubMedGoogle Scholar
  10. 10.
    Sampaio E, Sarno E, Galilly R, et al.: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699–703.PubMedCrossRefGoogle Scholar
  11. 11.
    Haslett P, Corral L, Albert M, Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187:1885–1892.PubMedCrossRefGoogle Scholar
  12. 12.
    Bartlett J, Dredge K, Dalgleish A: The evolution of thalidomide and its IMid derivatives as anticancer agents. Nat Rev Cancer 2004, 4:314–322.PubMedCrossRefGoogle Scholar
  13. 13.
    Nogueira A, Neubert R, Helge H, Neubert D: Thalidomide and the immune system. 3. Simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994, 55:77–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Marriott J, Clarke I, Dredge K, et al.: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunon 2002, 130:75–84.CrossRefGoogle Scholar
  15. 15.
    LeBlanc R, Hideshima T, Catley L, et al.: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103:1787–1790.PubMedCrossRefGoogle Scholar
  16. 16.
    Bartlett J, Michael A, Clarke I, et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004, 90:955–961.PubMedCrossRefGoogle Scholar
  17. 17.
    Tohnya T, Gulley J, Arlene P, et al.: Phase I study of senalidomide, a novel thalidomide analog in patients with refractory metastatic cancer [abstract]. Proc ASCO 2006, 24:605S (abstract 13038).Google Scholar
  18. 18.
    Cooney M, Gibbons J, Brell J, et al.: Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors [abstract]. Program Proceedings 2006 ASCO Prostate Cancer Symposium 2006:226 (abstract 265).Google Scholar
  19. 19.
    Moss R, Shelton G, Melia J, et al.: A phase I open label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer [abstract]. Proc ASCO 2006, 24:646s (abstract 14618).Google Scholar
  20. 20.
    Kalmadi S, Davis M, Dowlati A, et al.: Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors [abstract]. Proc ASCO 2006, 24:604s (abstract 13027).Google Scholar
  21. 21.
    Marsh L, Khan M, Needle M, Amato R: Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC) [abstract]. Proc ASCO 2006, 24:224 (abstract 4533).Google Scholar
  22. 22.
    Choueiri TK, Dreicer R, Rini BI, et al.: Phase II study of lenalidomide (Revlimid) in patients with metastatic renal cell carcinoma. Cancer 2006, 107:2609–2616.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of Solid Tumor Oncology, Taussig Cancer CenterThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations